North America (largest region, 38% share) dominates the canine atopic dermatitis treatment market growth through mature companion-animal insurance coverage, high pet-humanization spend (>US$2.5k per dog/year), and streamlined FDA/CFIA approvals that accelerate biologic and JAK-inhibitor launches. Europe (30%) leverages harmonized EMA regulatory pathways, mandatory pet micro-chipping that boosts prescription adherence tracking, and sustainability-focused ESG capital earmarked for veterinary R&D. Asia Pacific (fastest-growing, 20% CAGR) is fueled by urban pet boom (China >12m new dogs 2019-23), rising middle-class disposable income, and government subsidies for veterinary clinic build-outs; regional forecast models show treatment penetration doubling to 28% by 2028. Latin America (7%) benefits from Brazil’s recent zero-tariff import list for veterinary dermatology APIs, growing pet health-insurance uptake (+18% YoY), and private equity roll-ups modernizing 1,200+ clinics. Middle East & Africa (5%) sees uptake driven by GCC pet import regulations mandating allergy screening, South African veterinary telehealth platforms expanding rural reach, and sovereign funds channeling oil revenues into high-tech animal health hubs in UAE and Saudi Arabia.
